SSc is clinically and pathogenetically heterogeneous. Consensus standards for trial design and outcome measures are needed. International experts experienced in SSc clinical trial design and a researcher experienced in systematic literature review screened the PubMed and Cochrane Central Register of Controlled Trials in order to develop points to consider when planning a clinical trial for muscle involvement in SSc. The experts conclude that SSc-associated muscle involvement is heterogeneous and lacks a universally accepted gold-standard for measuring therapeutic response. Although outcome studies are currently limited by the inability to clearly distinguish active, reversible muscle inflammation from irreversible muscle damage and extramuscular organ involvement, strong consideration should be given to enrolling patients with a myopathy that features several elements of likely reversibility such as muscle weakness, biopsy-proven active inflammation, an MRI indicating muscle inflammation and a baseline serum creatinine kinase above three times the upper limit of normal to prevent floor effect. Randomized controlled trials are preferred, with a duration of at least 24 weeks. Outcome measures should include a combination of elements that are likely to be reversible, such as muscle weakness, biopsy-proven active inflammation, creatinine kinase/aldolase and a quality of life questionnaire. The individual measurements might require a short pre-study for further validation. A biological sample repository is recommended.
Introduction
Disease criteria have been developed to serve different functions. Classification criteria are important for clinical trials as they differentiate between patients with and without a disease, or cluster patients in disease subgroups. Damage, activity and prognostic criteria describe irreversible and reversible lesions, and extrapolate their evolution into the future. Finally, outcome criteria are intended to measure the overall impact of a disease and serve as dependent variables for clinical trials [1] . Outcome criteria may contain dimensions such as death, disability and discomfort, and contain medical or economic variables [1] .
The purpose of this article is to review the outcome criteria currently available for muscle involvement in SSc and to suggest points to consider when doing clinical trials of muscular involvement in this disease.
Prevalence of muscle involvement in SSc
The prevalence of muscle involvement in SSc varies widely, with estimates ranging from 5 to 96% [211] . The large variation in the prevalence of muscle involvement can be attributed to the lack of a uniformly accepted case definition of myopathy and to differences in specific SSc subsets that are analysed; muscle involvement is more common in patients with diffuse than limited SSc [7, 1214] . Many clinical findings and laboratory markers of myopathies lack specificity. Thus, the myopathy in SSc may also be part of the normal clinical spectrum of an overlapping second CTD. For instance, about 11% of patients with SSc may develop an inflammatory myopathy that fulfils the Bohan and Peter criteria for classic PM [10, 15, 16] . These examples highlight the challenges in the classification of muscular involvement. The exact definition of the population to be studied will clearly impact the outcome of the clinical trial.
Clinical manifestations
Clements et al. [4] examined 24 SSc patients for the presence of a myopathy with muscle strength testing, electromyography and serum muscle enzyme measurements. Two patterns emerged. The majority (79%) had a simple myopathy with mild proximal muscle weakness, normal or slight elevation of the creatine kinase (CK) and polyphasic motor unit potentials on EMG of normal duration and amplitudes. Muscle biopsy revealed interstitial fibrosis or muscle fibre diameter variation (bland myopathy), but there was no inflammation. The second pattern was termed complicated myopathy [4] . Patients had at least three of four features: symmetric weakness of the limbgirdle muscles and anterior neck flexors, inflammation on muscle biopsy, EMG evidence of membrane irritability in the form of short-duration, small-amplitude polyphasic motor units, fibrillations, positive sharp waves, and/ or insertional irritability, and elevation of the CK or aldolase.
Subsequent work, however, found, that the dichotomy into a simple and complicated myopathy as a predictor of the clinical course is not sufficient, as other variations in muscle disease also occur. For example, some SSc patients have elevated serum muscle enzymes without evidence of muscle inflammation on biopsy [17] , weakness without elevated muscle enzymes or prominent myopathology on EMG without clinical weakness [3, 5, 6, 18] . As a consequence of these variable patterns in the clinical and diagnostic features of muscle involvement in SSc, an established definition does not exist and varying definitions have been utilized in clinical studies [3, 7, 9, 13, 14, 1922] .
Recent work has assessed the muscle microcirculation using blood oxygenation level dependent (BOLD) MRI. This study suggests, that the vast majority of patients suffer from previously unrecognized microcirculatory impairment in SSc muscle, even patients not deemed to have any myopathy by conventional definitions [23] . Its use as an outcome measure is not recommended as research into this modality has just begun.
Muscle weakness
The prevalence of muscle weakness varies widely [4, 5] . Objective proximal muscle weakness was noted in only 10% of patients [24, 25] ; patient-reported weakness, however, was more frequent as $33% patients reported subjective muscle weakness [25] .
In the European Scleroderma Trials and Research (EUSTAR) group cohort and other cohorts, 2737% of patients with diffuse cutaneous SSc reported muscle weakness, as opposed to 2123% with lcSSc [12, 26] . Weakness may be present without elevated creatine kinase and it could be difficult to ascertain due to thickening of the overlying skin [27] .
Histology
Muscle biopsies reveal a variety of histopathology in SSc, such as fibrosis of the perimysium and epimysium [5, 6, 18, 28] , intimal proliferation of endomysial and perimysial vessels, perivascular infiltrates and muscle necrosis [3, 5, 6, 10, 17, 18, 28] . SSc patients may also have reduced numbers of muscle capillaries [29] and the remaining capillaries may have an increased diameter [30] . A muscle biopsy is more likely to be useful to diagnose the disease then to serve as an outcome measure.
Outcome measures
Among the tools used to evaluate muscle weakness, manual muscle testing (MMT) is reliable in inflammatory myositis (IIM) and its responsiveness to change has been demonstrated in a placebo-controlled trial [31] . Manual testing of 24 muscles in proximal, distal and axial muscle groups has demonstrated good inter-rater and intra-rater reliability, moderate sensitivity to change and good construct validity with global assessments and muscle functional measures [32] .
The sensitivity of MMT, however, depends on the size of the selected muscle group(s) and the strength of the tester [33] . MMT is further limited by its inability to detect weakness in patients with only mild strength impairment [33, 34] . Other sources of measurement error in MMT may be linked to diurnal effects, comprehension of the testing task, motor skills, state of arousal, level of motivation and difference in stature of the tested person relative to the tester [33] . Examiner based confounders include variations in force application and MMT grading, inconsistent commands, examiner inexperience and variable feedback to the tested person [32, 33] . Like other measures such as joint counts in RA and skin score in SSc, MMT of individual muscle groups (areas) has poor inter-rater reliability but, if it is to be considered, it should be standardized among the assessors. Inter-rater reliability can be improved with examiner training [32] . The amount of change in MMT that is clinically important has been neither ascertained nor validated [32] .
MMT has not been evaluated in SSc-associated myopathy and it is unclear how skin fibrosis or concomitant contractures will affect the MMT results [35] . The reversibility of muscle strength in SSc is unknown and MMT does not distinguish between the reversible weakness of active disease vs that due to irreversible muscle damage.
Tools other than MMT that measure muscle strength with acceptable reliability exist [32, 36] . These myometry devices are expensive and not feasible in multicentre clinical trials, particularly in SSc. Measuring aerobic exercise capacity as a parameter of muscular blood supply and therefore small vessel involvement [32] can be confounded by musculoskeletal (contractures, deconditioning), lung and myocardial complications in SSc. BOLD MRI may also be useful in the quantification of microcirculatory impairment in the skeletal muscle of SSc patients [23] .
Muscle pain
There are currently no data to support myalgia as an outcome measure in SSc because myalgia is entirely non-specific in SSc. In a placebo-controlled trial, muscle tenderness on palpation was unaffected by CYC [37] .
Questionnaires
The self-administered systemic sclerosis questionnaire (SySQ) has high reliability and validity and musculoskeletal function scales [38] . The SySQ has, however, not been used in clinical trials in SSc.
Muscle enzymes CK has not been published as validated in SSc although serum CK levels were found to correlate negatively with muscle strength in SSc [4, 39, 40] and a substantial number of patients with objective muscle weakness or abnormal muscle histology have normal CK levels [16, 18] . A normal serum CK does not reliably exclude the presence of SSc-associated myopathy [32] . The combination of serum CK and aldolase may increase diagnostic sensitivity [4] and interestingly, an elevated serum aldolase predicted the subsequent development of symptomatic muscle involvement related to SSc [41] .
Serum autoantibodies
Serum antibodies have no value as an outcome measure for muscle involvement in SSc. The presence of autoantibodies in the serum provides important clues for the diagnosis of muscle involvement and the prediction of its clinical course and response to therapy [10, 4245] . Longitudinal studies that quantify autoantibody titres are generally lacking or found no association with the evolution of the clinical phenotype [43] .
Electromyography
Although distal electromyographic findings correlate with disease progression and severity in both SSc subsets [8] , there is no established role of EMG as an outcome measure. There is also no association between EMG findings and CK or antibody levels [8] .
MRI techniques
The utility of MRI in SSc has been studied in only a few cases, in contrast to several studies in idiopathic inflammatory myopathies, such as DM [4649] in which muscle oedema was demonstrated. Phosphorus magnetic resonance spectroscopy [49] and BOLD MRI [23, 50] may in the future be utilized to enhance the yield of biopsy proven inflammation and to assess microvascular function, but these modalities have no current role as an outcome measure.
Survival
Death may be considered the most severe outcome of a disease. Cohort data indicate that muscle involvement worsens survival in SSc [9] with univariate linkage of proximal muscle weakness [51, 52] and CK elevation to premature death [40, 52] . After multivariate adjustment, muscle signs or symptoms no longer predicted mortality [52] . Another study also noted that severe muscle involvement, measured semiquantitatively, was associated with increased mortality, but there was no multivariate analysis [35] . These data indicate that survival as a primary outcome for a trial of SSc muscle involvement is likely to be confounded and it would not normally be used in an SSc myopathy trial. If considered as an outcome, this would need to be fully justified
Recommendations for points to consider for clinical trials
As seen from the above discussion, the SSc-associated muscle involvement is heterogeneous and lacks a universally accepted gold standard for its diagnosis and response to therapy. An important limitation of studies in SSc is the inability to distinguish active, reversible muscle inflammation from weakness caused by muscle damage [35] . Although the presence of muscular and/or articular complaints represents a component of the European SSc activity criteria, no measurement describing the activity of SSc muscle involvement has been developed [26, 53] .
While the International Myositis Assessment and Clinical Studies group has proposed definitions of improvement, worsening, complete clinical response and clinical remission in the idiopathic inflammatory myopathies [5456] , this group has now formulated points to consider for a clinical trial for muscle involvement in SSc. While the evidence may be Class A through D, the recommendations are Class C throughout.
Outcome measure
In the absence of clearly defined, validated measures of SSc myopathy, the best approach may be consensusbased with subsequent validation of the proposed measures. For example, some may wish to use MMT or selected muscle groups as the outcome measure. This might require a short 'pre-study' to validate most portions of the measure in SSc (although sensitivity to change v40 www.rheumatology.oxfordjournals.org could not be defined at that time). A steroid sparing study could also be considered as an exploratory outcome, although it would confound most other potential measures. Using MMT plus CK/aldolase, the self-administered SySQ [38] and simple visual analogue scales of weakness and myalgia in the pre-study could enable a study of muscle involvement (Class C recommendation).
Study design
Only controlled studies should be undertaken. Consideration should be given to a randomized controlled design. If placebo controlled, background or standard care therapy should be allowed with appropriate escape for meeting pre-defined failure criteria. Background therapy such as the duration and dose of allowed corticosteroids, corticosteroid tapering and the nature and intensity of physical therapy intervention must be defined and carefully recorded during the trial so as not to impair the assessment of the study drug (Class C recommendation).
Study duration
Trial duration should be at least 24 weeks if CK, aldolase and the SySQ are used as outcome measures. Duration of a trial assessing muscle involvement may have to be longer, depending on the intervention being studied.
Inclusion criteria
In order to establish a relatively uniform and identifiable patient group, patients should fulfil either the ACR [57] , or the ACR/EULAR [58] or the LeRoy criteria [59] for SSc. The auto-antibody profile for study inclusion should be stated [9, 10, 12, 20, 43, 6066 ] to allow uniformity, subanalyses based on auto-antibody status and/or comparison between study groups. Patients should be confined to either adult (usually >18 years of age) or childhood groupings (usually <18 years of age).
Another reason for inclusion criteria is to define responsive patients: Strong consideration should be given to enrolling patients with inflammatory muscle involvement that feature several elements of likely reversibility such as muscle weakness, biopsy-proven active inflammation [4, 7, 67] , an MRI indicating muscle inflammation, and a baseline CK >3Â upper limit of normal. While this degree of elevation is arbitrary, it is reasonable to prevent floor effects. Other CK entry criteria can be used, particularly if a consensus among investigators is reached. Muscle enzymes other than CK could be considered including aldolase (Class C recommendation).
Although we realize that not all patients with SSc muscle involvement are weak, weakness brings patients to the physician and would most often be the prime reason for requesting therapy. It would therefore logically be an important measure in an SSc trial of myopathy. Therefore, to enhance uniformity in a clinical trial and because it is a primary complaint in many SSc patients, we feel that weakness should be considered a sine qua non in most clinical trials of SSc myopathy. On the other hand, some patients may be so strong that their subjective weakness may not be discernible. If weakness is not a primary outcome, trials may wish to consider the CK instead of weakness. The lack of a gold standard for SSc myopathy emphasizes the need to consider preliminary research to establish valid outcomes for any given trial.
The measure of muscle weakness should likely include MMT due to convenience and low expense. A training session on MMT is essential and one should consider utilizing physical therapists and insuring the same examiner throughout the trial [68] (Class C recommendation). Myometry and endurance testing are unlikely to be used because they are impractical, expensive and unvalidated
Exclusion criteria
As for inclusion criteria, exclusion criteria help to establish patient uniformity as well as defining patients without complicating illnesses that might confound response. Concomitant illnesses known to prevent adequate patient assessment or known to pose an added risk for study participants such as stroke, diabetes mellitus, cancer, neuropathy, malnutrition, thyroid disease, peripheral arterial occlusive disease and OA should be exclusion criteria.
Drugs known to induce myositis or myopathic syndromes, including but not limited to statins, fibric acid derivatives, colchicine, HCQ and zidovudine, should be excluded or at least not initiated during the trial.
Consideration should be given to SSc manifestations that could confound outcomes, such as cardiopulmonary involvement, contractures, arthritis, etc.
Outcome measures
Measures of physician global disease activity, parent/patient global disease activity, MMT, physical function assessed by SySQ, extramuscular disease manifestations and laboratory measurements have been used in a placebo-controlled, multicentre trial of adult and juvenile DM and adult PM [69] , but none of these measures have been validated in SSc. Thus, in SSc patients with inflammatory myopathy consideration should be given to utilizing core set measures and definitions of improvement developed by consensus among myositis experts [54] .
Prior to initiating a large controlled trial, the proposed measures should be assessed for face criterion, construct and content validity, reliability/reproducibility and feasibility, even though some core measures may have been validated in idiopathic IIM [54, 68] .
A myopathy trial in SSc should include a measure of quality of life (e.g. SF-36, Class C recommendation). It is also recommended that a biological sample repository be developed.
Analysis
In early studies of muscle involvement, the analysis of the validation studies should consider including intra-class correlations, and measures of reproducibility and reliability. It may be useful to compare the degrees of agreement among measures by means of correlations.
At a minimum, it is recommended to describe the patient disposition (using a table or figure) and a table describing patient groups at enrolment including demographics, autoantibody status, other ancillary disease characteristics and outcome measurements. Comparisons among the groups to establish baseline uniformity are strongly recommended (Class C recommendation).
It is recommended to describe a predefined analysis plan that includes an algorithm to deal with missing data and drop-outs (Class C recommendation). To ensure uniformity of groups when comparing therapies, multiple methods can be used. These include stratification (e.g. by CK, steroid dose, steroid use duration, SSc subset, autoantibody status or disease duration (Class C recommendation), inclusion of variables as independent variables in regression analyses and others. The specific approach will depend on the objectives and study design. It is critical that such considerations be outlined prior to initiation of the study.
Conclusion
SSc-associated myopathy is heterogeneous and lacks a universally accepted gold-standard for measuring therapeutic response. Randomized controlled trials are preferred, with a duration of at least 24 weeks. Study enrolment should preferentially consider patients with a myopathy featuring several elements of likely reversibility. Outcome measures should include quality of life questionnaires, muscle weakness, enzymes and biopsy-proven inflammation. Individual measurements might require a short 'pre-study' for further validation.
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